B. longum: stress and sleep
Results of NCC3001 and 1714 studies for stress and sleep.
Key points
- In healthy adults with mild or moderate stress, NCC3001 reduced self-rated stress over six weeks by 3.28 points more than placebo on a scale up to 56. No significant advantage was found on a separate anxiety scale. [1] See the evidence 1 2
- In adults with sleep complaints, strain 1714 showed no advantage over eight weeks on the overall sleep questionnaire or wrist-worn device measures. In the NCC3001 stress study, the overall sleep measure also did not differ significantly from placebo. [2] [1] See the evidence 1 2 3
Practical guide
Check the findings and their applicability to your situation.
The studies separately assessed stress, anxiety and sleep measures.
Key points
Why these conclusions
Studies of stress and sleep
Healthy adults with mild or moderate stress took 10 billion CFU of NCC3001 daily or placebo for six weeks. The stress score was 3.28 points lower out of 56; no significant advantage was found for anxiety or the overall sleep measure. Certainty is low — 2 out of 4. [1]
Adults with sleep complaints without diagnosed insomnia took 1 billion CFU of strain 1714 daily for eight weeks. The overall sleep score and wrist-worn device measures did not differ significantly from placebo; early differences in individual questionnaire items did not remain significant after adjustment for multiple comparisons. [2]
The perceived stress score PSS on a 0–56 scale was 3.28 points lower than with placebo. The 95% confidence interval was a reduction of 0.62–5.93 points; p = 0.017.
| Parameter | Data |
|---|---|
| Result | The perceived stress score PSS on a 0–56 scale was 3.28 points lower than with placebo. The 95% confidence interval was a reduction of 0.62–5.93 points; p = 0.017. |
| Participants | 49 healthy adults aged 25–65 with mild or moderate stress; 45 entered the main analysis |
| Form | Powder with live NCC3001 in a sachet |
| Dose | 10 billion CFU daily: one sachet dissolved in about 50 mL of water, with breakfast |
| Dose basis | 10 billion CFU daily: one sachet dissolved in about 50 mL of water, with breakfast |
| Comparison | Powder with maltodextrin, yeast extract, cysteine and pea flour, without NCC3001 |
| Duration | 6 weeks |
| Certainty | 2/4: A small exploratory trial: 49 people were allocated to groups, 45 entered the main analysis. This is self-rated stress in generally healthy adults; the result does not mean that all anxiety symptoms decrease. |
| Body of evidence | publication |
| Sources | [1] |
The difference on the HADS-A anxiety scale was −0.65 points; 95% confidence interval from −2.05 to 0.76 points, p = 0.358.
| Parameter | Data |
|---|---|
| Result | The difference on the HADS-A anxiety scale was −0.65 points; 95% confidence interval from −2.05 to 0.76 points, p = 0.358. |
| Participants | 49 healthy adults aged 25–65 with mild or moderate stress; 45 entered the main analysis |
| Form | Powder with live NCC3001 in a sachet |
| Dose | 10 billion CFU daily: one sachet dissolved in about 50 mL of water, with breakfast |
| Dose basis | 10 billion CFU daily: one sachet dissolved in about 50 mL of water, with breakfast |
| Comparison | Powder with maltodextrin, yeast extract, cysteine and pea flour, without NCC3001 |
| Duration | 6 weeks |
| Certainty | 2/4: Anxiety was a separate measure in a small trial in people with elevated stress. The interval includes both a decrease and a small increase in score; it does not show exact equivalence between the two intake options. |
| Body of evidence | publication |
| Sources | [1] |
After 8 weeks, the overall PSQI sleep quality score on a 0–21 scale was 4.0 versus 4.3 with placebo; p = 0.64. A lower score means fewer sleep problems.
| Parameter | Data |
|---|---|
| Result | After 8 weeks, the overall PSQI sleep quality score on a 0–21 scale was 4.0 versus 4.3 with placebo; p = 0.64. A lower score means fewer sleep problems. |
| Participants | 89 adults aged 18–45 with sleep complaints; 87 entered the analysis. Participants did not have diagnosed insomnia |
| Form | Capsule containing live strain 1714 |
| Dose | 1 billion CFU daily: one capsule in the morning with or after food |
| Dose basis | 1 billion CFU daily: one capsule in the morning with or after food |
| Comparison | Capsule with corn starch and magnesium stearate, without 1714 |
| Duration | 8 weeks |
| Certainty | 2/4: Participants had sleep complaints but no diagnosed insomnia. In some people complaints had already decreased between screening and the start of intake; the result applies to this group and eight weeks. |
| Body of evidence | publication |
| Sources | [2] |
The difference in total PSQI score was −0.38 points; 95% confidence interval from −1.13 to 0.37 points, p = 0.308.
| Parameter | Data |
|---|---|
| Result | The difference in total PSQI score was −0.38 points; 95% confidence interval from −1.13 to 0.37 points, p = 0.308. |
| Participants | 49 healthy adults aged 25–65 with mild or moderate stress; 45 entered the main analysis |
| Form | Powder with live NCC3001 in a sachet |
| Dose | 10 billion CFU daily: one sachet dissolved in about 50 mL of water, with breakfast |
| Dose basis | 10 billion CFU daily: one sachet dissolved in about 50 mL of water, with breakfast |
| Comparison | Powder with maltodextrin, yeast extract, cysteine and pea flour, without NCC3001 |
| Duration | 6 weeks |
| Certainty | 2/4: Sleep was assessed additionally in a small trial in people with stress; many had no marked sleep disturbances at baseline. The conclusion concerns the total PSQI score. A separate assessment of subjective sleep quality does not replace this measure. |
| Body of evidence | publication |
| Sources | [1] |
In weeks 5–8, the proportion of time asleep was 92% versus 91% with placebo; on average the device recorded 15 versus 16 awakenings. Differences in these measures, time to fall asleep and wakefulness after sleep onset were not statistically significant.
| Parameter | Data |
|---|---|
| Result | In weeks 5–8, the proportion of time asleep was 92% versus 91% with placebo; on average the device recorded 15 versus 16 awakenings. Differences in these measures, time to fall asleep and wakefulness after sleep onset were not statistically significant. |
| Participants | 89 adults aged 18–45 with sleep complaints; 87 entered the analysis. Participants did not have diagnosed insomnia |
| Form | Capsule containing live strain 1714 |
| Dose | 1 billion CFU daily: one capsule in the morning with or after food |
| Dose basis | 1 billion CFU daily: one capsule in the morning with or after food |
| Comparison | Capsule with corn starch and magnesium stearate, without 1714 |
| Duration | 8 weeks |
| Certainty | 2/4: A wrist-worn device assessed sleep by movement; this is a separate measure from questionnaire responses. For four measures, p values were 0.95, 0.29, 0.69 and 0.34. The trial did not study treatment of diagnosed insomnia. |
| Body of evidence | publication |
| Sources | [2] |
After 4 weeks, the sleep quality score was 1.0 versus 1.2 points, and daytime difficulties 0.5 versus 0.7 with placebo, on 0–3 scales. After adjustment for multiple comparisons these differences were no longer statistically significant.
| Parameter | Data |
|---|---|
| Result | After 4 weeks, the sleep quality score was 1.0 versus 1.2 points, and daytime difficulties 0.5 versus 0.7 with placebo, on 0–3 scales. After adjustment for multiple comparisons these differences were no longer statistically significant. |
| Participants | 89 adults aged 18–45 with sleep complaints; 87 entered the analysis. Participants did not have diagnosed insomnia |
| Form | Capsule containing live strain 1714 |
| Dose | 1 billion CFU daily: one capsule in the morning with or after food |
| Dose basis | 1 billion CFU daily: one capsule in the morning with or after food |
| Comparison | Capsule with corn starch and magnesium stearate, without 1714 |
| Duration | 8 weeks |
| Certainty | 1/4: These are individual parts of the questionnaire, not its total score. Researchers simultaneously tested many measures, increasing the chance of a chance difference. At eight weeks there was no sustained advantage on these questionnaire parts. |
| Body of evidence | publication |
| Sources | [2] |
Information from the source
In healthy people, live probiotics can cause gas and other intestinal complaints. Inactivated cells also do not rule out adverse reactions: the HT-ES1 trial described stomach pain, gas and a possible association with nausea, bloating and reflux. In severe illness or markedly weakened immunity, live probiotics may increase the risk of infection. In these situations, discuss product choice and monitoring with a doctor. The risk is particularly important for preterm infants: the FDA described a case of B. longum sepsis and the death of an infant after a hospital product containing live bacteria. This case does not establish the frequency of complications in healthy adults. Check not only the bacteria but also the other ingredients. For example, the CLA8013 capsule shell in the trial described contained porcine gelatin and soy lecithin; another product may have a different composition. [3] [4] [5] [6] [7]
Information from the source
Live bacteria. BB536, NCC3001, 1714, 35624, ES1, BL21 and APC1472 are different strains. Look on the package for the full code, CFU count through the end of shelf life and storage conditions. More CFU alone does not mean more benefit. Inactivated cells. CLA8013 and HT-ES1 were heat-treated in these trials. Their doses are expressed as numbers of cells or cell equivalents, not numbers of live bacteria. Even for HT-ES1, doses differed: 2.5 billion cells in digestive studies and 2 billion for allergic rhinitis. Strain 35624. In an early publication it was called B. infantis 35624. In the trial of pain in IBS, capsules containing 100 million CFU daily showed an advantage; this is not a general result for all doses or all B. longum products. [7] [4] [3] [8]
Sources
- Bifidobacterium longum subsp. longum Reduces Perceived Psychological Stress in Healthy Adults: An Exploratory Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/37513541/
- Bifidobacterium longum 1714 improves sleep quality and aspects of well-being in healthy adults: a randomized, double-blind, placebo-controlled clinical trial. https://pubmed.ncbi.nlm.nih.gov/38355674/
- Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study. https://pubmed.ncbi.nlm.nih.gov/39599737/
- Effects of Bifidobacterium longum CLA8013 on bowel movement improvement: a placebo-controlled, randomized, double-blind study. https://pubmed.ncbi.nlm.nih.gov/37404567/
- Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or Yeast (FDA). https://www.fda.gov/safety/medical-product-safety-information/risk-invasive-disease-preterm-infants-given-probiotics-formulated-contain-live-bacteria-or-yeast
- Probiotics: Usefulness and Safety (NCCIH). https://www.nccih.nih.gov/health/probiotics-usefulness-and-safety
- Probiotics — Fact Sheet for Consumers (NIH ODS). https://ods.od.nih.gov/factsheets/Probiotics-Consumer/
- Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. https://pubmed.ncbi.nlm.nih.gov/16863564/
Methodology: Subpages evidence-led supplement pipeline v1